Supplementary Table 1. Concomitant Use of Oral 5-ASA Preparations (Safety Analysis Population; n = 633)

Variable		Value
No. of cases analyzed[a]		579
Concomitant oral 5-ASA dosage (mg/day)	Mean ± SD	3,904.4 ± 948.1
	Median	4,000.0
Patients by concomitant dosage, No. (%)[b]	≤ 2,400 mg/day	85 (14.7)
	> 2,400 mg/day and ≤ 4,000 mg/day	248 (42.9)
	> 4,000 mg/day	245 (42.4)
	Unknown	1 (NA)

[a]Of the patients included in the safety analysis, those who had received an oral 5-ASA preparation at the time of concomitant administration were included.
[b]The denominator was the number of patients who had received an oral 5-ASA preparation at the time of concomitant administration; cases were defined as those in which the dose of the oral 5-ASA preparation at the time of concomitant administration was "unknown" were excluded. The proportion of cases with combined doses was calculated for 578 cases, excluding the 1 case marked unknown.
5-ASA, 5-aminosalicylic acid; SD, standard deviation; NA, not applicable.